Agile Therapeutics, Inc. (NASDAQ:AGRX) Given Consensus Recommendation of “Buy” by Analysts
Agile Therapeutics, Inc. (NASDAQ:AGRX) has been assigned an average recommendation of “Buy” from the eight brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $10.40.
Several brokerages have issued reports on AGRX. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Sunday, July 30th. Janney Montgomery Scott reiterated a “buy” rating and set a $15.00 target price on shares of Agile Therapeutics in a research report on Friday, July 21st. HC Wainwright began coverage on shares of Agile Therapeutics in a research report on Wednesday, July 19th. They set a “buy” rating and a $10.00 target price for the company. Royal Bank Of Canada set a $8.00 target price on shares of Agile Therapeutics and gave the company a “buy” rating in a research report on Sunday, July 16th. Finally, ValuEngine upgraded shares of Agile Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 8th.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/12/agile-therapeutics-inc-nasdaqagrx-given-consensus-recommendation-of-buy-by-analysts.html.
Several large investors have recently made changes to their positions in the company. Franklin Resources Inc. raised its stake in shares of Agile Therapeutics by 39.2% in the second quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock worth $10,396,000 after buying an additional 780,578 shares during the last quarter. Royce & Associates LP raised its stake in shares of Agile Therapeutics by 1.1% in the second quarter. Royce & Associates LP now owns 998,582 shares of the specialty pharmaceutical company’s stock worth $3,745,000 after buying an additional 11,000 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Agile Therapeutics by 604.2% in the second quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock worth $359,000 after buying an additional 82,213 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Agile Therapeutics by 209.2% in the fourth quarter. Renaissance Technologies LLC now owns 64,000 shares of the specialty pharmaceutical company’s stock worth $365,000 after buying an additional 43,300 shares during the last quarter. Finally, LMR Partners LLP acquired a new stake in shares of Agile Therapeutics during the second quarter worth $211,000. Hedge funds and other institutional investors own 79.89% of the company’s stock.
Agile Therapeutics (NASDAQ AGRX) opened at 3.30 on Friday. The company’s market cap is $95.06 million. The company has a 50-day moving average of $4.07 and a 200 day moving average of $3.25. Agile Therapeutics has a 52 week low of $1.82 and a 52 week high of $8.15.
Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02. During the same quarter in the prior year, the business earned ($0.29) EPS. On average, equities analysts forecast that Agile Therapeutics will post ($1.05) EPS for the current fiscal year.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.